Inspire Medical Systems reported preliminary fourth-quarter and full-year revenue results that underscore sustained adoption of its Inspire V system for obstructive sleep apnea. While the company did not disclose absolute revenue figures, management highlighted a marked year-over-year increase driven by expanded procedural volumes across its U.S. and select international markets. This performance follows the mid-year software upgrade to Inspire V, implemented July 1, which the company attributes to improved ease of use for physicians and broader reimbursement acceptance under CPT code 64568.

For fiscal 2026, Inspire has provided initial revenue guidance calling for 10% to 11% year-over-year growth. This outlook excludes any incremental impact from recent reimbursement enhancements, which the company deems a positive development and is actively pursuing through engagement with relevant payors and regulatory agencies. Management reiterated confidence that procedural billing under code 64568—established with FDA approval in 2014—will continue to underpin predictable reimbursement and support margin expansion as adoption of the Inspire V system accelerates.